Azelaic acid

Full Generic Medicine Info
Dosage/Direction for Use

Acne vulgaris
Adult: As 20% cream or 15% gel: Apply thinly into the affected areas bid (morning and evening) after cleansing. Improvement may be detectable w/n 4 wk. Duration of treatment: Up to 6 mth.
Child: ≥12 yr Same as adult dose.

Adult: As 15% gel: Apply thinly into the affected areas bid (morning and evening). Improvement occurs in 4-8 wk.
Child: ≥12 yr Same as adult dose.

Special Populations: Acne vulgaris: Patients w/ sensitive skin: As 20% cream: Apply once daily (in the evening) for 1 wk then apply bid thereafter.
Special Precautions
Patient w/ sensitive skin. Not intended for application to broken, sunburnt or eczematous skin. Avoid use of occlusive dressing or wrappings. Pregnancy and lactation. Monitoring Parameters Monitor for hypopigmentation in patients w/ dark complexion.
Adverse Reactions
Burning, erythema, stinging, pruritus, dryness and scaling, peeling, irritation, dermatitis, hypopigmentation, rash, and photosensitivity. Rarely, exacerbation of asthma.
Food Interaction
Avoid spicy foods, alcoholic beverages and hot drinks that might provoke erythema, flushing and blushing during treatment of rosacea.
Azelaic acid is a naturally-occurring aliphatic dicarboxylic acid that inhibits the growth of Propionibacterium acnes and reduces keratinisation, thus restricts the development of comedones.
Onset: W/n 4 wk.
Absorption: Approx 4% absorbed systemically.
Distribution: Penetrates all layers of the skin.
Metabolism: Metabolised via β-oxidation into short-chained dicarboxylic acids (C7, C5).
Excretion: Via urine (mainly as unchanged drug and some as dicarboxylic acids). Half-life: 12 hr.
Topical/Cutaneous: Store between 15-30°C.
ATC Classification
D10AX03 - azelaic acid ; Belongs to the class of other topical preparations used in the treatment of acne.
Disclaimer: This information is independently developed by CIMS based on azelaic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in